JP3910798B2 - Ｍｎ遺伝子およびタンパク質 - Google Patents
Ｍｎ遺伝子およびタンパク質 Download PDFInfo
- Publication number
- JP3910798B2 JP3910798B2 JP2000578465A JP2000578465A JP3910798B2 JP 3910798 B2 JP3910798 B2 JP 3910798B2 JP 2000578465 A JP2000578465 A JP 2000578465A JP 2000578465 A JP2000578465 A JP 2000578465A JP 3910798 B2 JP3910798 B2 JP 3910798B2
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cells
- seq
- cell
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 400
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 334
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 132
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 92
- 229920001184 polypeptide Polymers 0.000 claims abstract description 67
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 29
- 230000012010 growth Effects 0.000 claims abstract description 19
- 230000001855 preneoplastic effect Effects 0.000 claims abstract description 16
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 102000004127 Cytokines Human genes 0.000 claims abstract description 6
- 108090000695 Cytokines Proteins 0.000 claims abstract description 6
- 239000003145 cytotoxic factor Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 312
- 230000014509 gene expression Effects 0.000 claims description 83
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 238000003352 cell adhesion assay Methods 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 210000005170 neoplastic cell Anatomy 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 6
- 108020004440 Thymidine kinase Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 230000001472 cytotoxic effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 230000027455 binding Effects 0.000 abstract description 80
- 239000013598 vector Substances 0.000 abstract description 26
- 230000035897 transcription Effects 0.000 abstract description 14
- 238000013518 transcription Methods 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 230000017455 cell-cell adhesion Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 308
- 239000002299 complementary DNA Substances 0.000 description 74
- 102000003846 Carbonic anhydrases Human genes 0.000 description 73
- 108090000209 Carbonic anhydrases Proteins 0.000 description 73
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 66
- 230000000694 effects Effects 0.000 description 66
- 108700012439 CA9 Proteins 0.000 description 62
- 206010028980 Neoplasm Diseases 0.000 description 54
- 238000000034 method Methods 0.000 description 50
- 102100030385 Granzyme B Human genes 0.000 description 44
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 44
- 235000001014 amino acid Nutrition 0.000 description 43
- 201000001130 congenital generalized lipodystrophy type 1 Diseases 0.000 description 42
- 150000001413 amino acids Chemical class 0.000 description 40
- 201000001113 congenital generalized lipodystrophy type 3 Diseases 0.000 description 39
- 101150020392 Cgl3 gene Proteins 0.000 description 38
- 102000015636 Oligopeptides Human genes 0.000 description 33
- 108010038807 Oligopeptides Proteins 0.000 description 33
- 201000011510 cancer Diseases 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 30
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 239000012634 fragment Substances 0.000 description 27
- 230000021164 cell adhesion Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 21
- 239000002773 nucleotide Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 230000003834 intracellular effect Effects 0.000 description 19
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 238000001262 western blot Methods 0.000 description 16
- 210000004408 hybridoma Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 108091023040 Transcription factor Proteins 0.000 description 14
- 102000040945 Transcription factor Human genes 0.000 description 14
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 14
- 229960000571 acetazolamide Drugs 0.000 description 14
- 108700009124 Transcription Initiation Site Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 12
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 108010044467 Isoenzymes Proteins 0.000 description 10
- 241000714177 Murine leukemia virus Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 238000003127 radioimmunoassay Methods 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 230000002860 competitive effect Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 210000004754 hybrid cell Anatomy 0.000 description 9
- 230000000381 tumorigenic effect Effects 0.000 description 9
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 8
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 8
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 241000700618 Vaccinia virus Species 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 231100000588 tumorigenic Toxicity 0.000 description 8
- 108091035707 Consensus sequence Proteins 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000030944 contact inhibition Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000005026 transcription initiation Effects 0.000 description 6
- 210000003501 vero cell Anatomy 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 108091023043 Alu Element Proteins 0.000 description 5
- 101000693922 Bos taurus Albumin Proteins 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 101150055766 cat gene Proteins 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000010307 cell transformation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000006740 morphological transformation Effects 0.000 description 5
- 231100001221 nontumorigenic Toxicity 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000007480 spreading Effects 0.000 description 5
- 238000003892 spreading Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical class NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091033380 Coding strand Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100024644 Carbonic anhydrase 4 Human genes 0.000 description 3
- 101710167916 Carbonic anhydrase 4 Proteins 0.000 description 3
- 101710167912 Carbonic anhydrase 6 Proteins 0.000 description 3
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000192019 Human endogenous retrovirus K Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- -1 MN mRNA Chemical class 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 102000007999 Nuclear Proteins Human genes 0.000 description 3
- 108010089610 Nuclear Proteins Proteins 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108700005075 Regulator Genes Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000008611 intercellular interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NDJNDUULNXNRQD-XKBRQERYSA-N 1-[(2r,4s,5s)-5-[bromo(hydroxy)methyl]-4-hydroxyoxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](C(Br)O)O[C@H]1N1C(=O)NC(=O)C=C1 NDJNDUULNXNRQD-XKBRQERYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 102000015936 AP-1 transcription factor Human genes 0.000 description 2
- 108050004195 AP-1 transcription factor Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100024650 Carbonic anhydrase 3 Human genes 0.000 description 2
- 101710167915 Carbonic anhydrase 3 Proteins 0.000 description 2
- 101710167910 Carbonic anhydrase 7 Proteins 0.000 description 2
- 102100036368 Carbonic anhydrase 7 Human genes 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 229920000288 Keratan sulfate Polymers 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 240000002390 Pandanus odoratissimus Species 0.000 description 2
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002622 anti-tumorigenesis Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000010397 one-hybrid screening Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- AKWUNZFZIXEOPV-UHFFFAOYSA-N 2-[4-[[3-[7-chloro-1-(oxan-4-ylmethyl)indol-3-yl]-1,2,4-oxadiazol-5-yl]methyl]piperazin-1-yl]acetamide Chemical compound C1CN(CC(=O)N)CCN1CC1=NC(C=2C3=CC=CC(Cl)=C3N(CC3CCOCC3)C=2)=NO1 AKWUNZFZIXEOPV-UHFFFAOYSA-N 0.000 description 1
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 description 1
- 101100280477 Caenorhabditis elegans lbp-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000999998 Homo sapiens Aggrecan core protein Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000760643 Homo sapiens Carbonic anhydrase 2 Proteins 0.000 description 1
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108050004689 Inhibitor of carbonic anhydrases Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 108091006036 N-glycosylated proteins Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 108091026828 U2 spliceosomal RNA Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000001116 congenital generalized lipodystrophy type 4 Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000043967 human ACAN Human genes 0.000 description 1
- 102000057327 human CA2 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091008600 receptor tyrosine phosphatases Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000010066 viral adhesion Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 229940006486 zinc cation Drugs 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/178,115 | 1998-10-23 | ||
| US09/178,115 US6297041B1 (en) | 1992-03-11 | 1998-10-23 | MN gene and protein |
| US09/177,776 | 1998-10-23 | ||
| US09/177,776 US6297051B1 (en) | 1997-01-24 | 1998-10-23 | MN gene and protein |
| PCT/US1999/024879 WO2000024913A2 (en) | 1998-10-23 | 1999-10-22 | Mn gene and protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006318591A Division JP4044597B2 (ja) | 1998-10-23 | 2006-11-27 | Ｍｎ遺伝子およびタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002528085A JP2002528085A (ja) | 2002-09-03 |
| JP2002528085A5 JP2002528085A5 (enExample) | 2005-07-07 |
| JP3910798B2 true JP3910798B2 (ja) | 2007-04-25 |
Family
ID=26873634
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578465A Expired - Fee Related JP3910798B2 (ja) | 1998-10-23 | 1999-10-22 | Ｍｎ遺伝子およびタンパク質 |
| JP2006318591A Expired - Lifetime JP4044597B2 (ja) | 1998-10-23 | 2006-11-27 | Ｍｎ遺伝子およびタンパク質 |
| JP2007233872A Expired - Fee Related JP4488373B2 (ja) | 1998-10-23 | 2007-09-10 | Ｍｎ遺伝子およびタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006318591A Expired - Lifetime JP4044597B2 (ja) | 1998-10-23 | 2006-11-27 | Ｍｎ遺伝子およびタンパク質 |
| JP2007233872A Expired - Fee Related JP4488373B2 (ja) | 1998-10-23 | 2007-09-10 | Ｍｎ遺伝子およびタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1123387B1 (enExample) |
| JP (3) | JP3910798B2 (enExample) |
| AT (1) | ATE376056T1 (enExample) |
| AU (1) | AU758957C (enExample) |
| CA (1) | CA2347649C (enExample) |
| CY (1) | CY1107268T1 (enExample) |
| DE (1) | DE69937364T2 (enExample) |
| DK (1) | DK1123387T3 (enExample) |
| ES (1) | ES2296412T3 (enExample) |
| NO (1) | NO328884B1 (enExample) |
| WO (1) | WO2000024913A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6902890B1 (en) | 1999-11-04 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing monitoring, staging, imaging and treating cancer |
| US20040077081A1 (en) | 2001-02-07 | 2004-04-22 | Egbert Oosterwijk | Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| AR036833A1 (es) * | 2001-10-18 | 2004-10-06 | Bayer Corp | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular. |
| US7910549B2 (en) * | 2001-12-13 | 2011-03-22 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
| CA2477163C (en) | 2002-02-21 | 2010-07-27 | Institute Of Virology | Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes |
| SI2508596T1 (sl) | 2002-02-21 | 2016-01-29 | Institute Of Virology Slovak Academy Of Sciences | Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe |
| AU2003223186A1 (en) * | 2002-05-23 | 2004-01-23 | Bayer Healthcare | SOLUBLE FORM OF CARBONIC ANHYDRASE IX (s-CA IX), ASSAYS TO DETECT s-CA IX AND CA IX's COEXPRESSION WITH HER-2/neu/c-erbB-2 |
| EP1524995B1 (en) | 2002-07-01 | 2011-12-21 | Wilex AG | Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| AU2003268180A1 (en) * | 2002-08-23 | 2004-03-11 | Chiron Corporation | Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |
| US7550424B2 (en) | 2002-11-26 | 2009-06-23 | Institute Of Virology Slovak Academy Of Sciences | CA IX-specific inhibitors |
| US7524634B2 (en) * | 2003-10-16 | 2009-04-28 | Institute Of Virology, Slovak Academy Of Sciences | MN/CA IX and cancer prognosis |
| AU2005241093B2 (en) | 2004-05-04 | 2008-06-05 | Institute Of Virology Of Slovak Academy Of Sciences | MN/CA IX/ CA9 and renal cancer prognosis |
| US7820159B2 (en) | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
| US8399624B1 (en) * | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
| ES2703572T3 (es) | 2013-02-22 | 2019-03-11 | Heidelberg Pharma Ag | Tratamiento del cáncer basado en la estratificación de CAIX |
| CZ2014527A3 (cs) * | 2014-08-05 | 2016-02-17 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2192678C (en) * | 1994-06-15 | 2010-12-14 | Jan Zavada | Mn gene and protein |
| US6329501B1 (en) * | 1997-05-29 | 2001-12-11 | Auburn University | Methods and compositions for targeting compounds to muscle |
| AU3714499A (en) * | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
-
1999
- 1999-10-22 EP EP99955151A patent/EP1123387B1/en not_active Expired - Lifetime
- 1999-10-22 DE DE69937364T patent/DE69937364T2/de not_active Expired - Lifetime
- 1999-10-22 AU AU11323/00A patent/AU758957C/en not_active Expired
- 1999-10-22 WO PCT/US1999/024879 patent/WO2000024913A2/en not_active Ceased
- 1999-10-22 JP JP2000578465A patent/JP3910798B2/ja not_active Expired - Fee Related
- 1999-10-22 EP EP06076937A patent/EP1832653A1/en not_active Withdrawn
- 1999-10-22 ES ES99955151T patent/ES2296412T3/es not_active Expired - Lifetime
- 1999-10-22 DK DK99955151T patent/DK1123387T3/da active
- 1999-10-22 CA CA2347649A patent/CA2347649C/en not_active Expired - Lifetime
- 1999-10-22 AT AT99955151T patent/ATE376056T1/de active
-
2001
- 2001-04-19 NO NO20011926A patent/NO328884B1/no not_active IP Right Cessation
-
2006
- 2006-11-27 JP JP2006318591A patent/JP4044597B2/ja not_active Expired - Lifetime
-
2007
- 2007-09-10 JP JP2007233872A patent/JP4488373B2/ja not_active Expired - Fee Related
-
2008
- 2008-01-16 CY CY20081100058T patent/CY1107268T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU758957B2 (en) | 2003-04-03 |
| DE69937364T2 (de) | 2008-07-17 |
| JP4488373B2 (ja) | 2010-06-23 |
| EP1832653A1 (en) | 2007-09-12 |
| WO2000024913A2 (en) | 2000-05-04 |
| CA2347649A1 (en) | 2000-05-04 |
| ATE376056T1 (de) | 2007-11-15 |
| WO2000024913A3 (en) | 2000-09-14 |
| CA2347649C (en) | 2012-03-13 |
| JP2002528085A (ja) | 2002-09-03 |
| AU1132300A (en) | 2000-05-15 |
| JP2008069151A (ja) | 2008-03-27 |
| NO20011926L (no) | 2001-06-19 |
| NO20011926D0 (no) | 2001-04-19 |
| AU758957C (en) | 2004-08-12 |
| EP1123387A2 (en) | 2001-08-16 |
| EP1123387B1 (en) | 2007-10-17 |
| DK1123387T3 (da) | 2008-02-25 |
| DE69937364D1 (de) | 2007-11-29 |
| CY1107268T1 (el) | 2012-11-21 |
| JP2007145843A (ja) | 2007-06-14 |
| ES2296412T3 (es) | 2008-04-16 |
| NO328884B1 (no) | 2010-06-07 |
| JP4044597B2 (ja) | 2008-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4488373B2 (ja) | Ｍｎ遺伝子およびタンパク質 | |
| JP5021717B2 (ja) | Ｍｎ遺伝子およびタンパク質 | |
| US20090118473A1 (en) | MN Gene and Protein | |
| US7816496B2 (en) | MN gene and protein | |
| US20020137910A1 (en) | MN gene and protein | |
| CA2192678C (en) | Mn gene and protein | |
| US8334137B2 (en) | MN gene and protein | |
| JP2004520805A (ja) | Ｐａｒ−１キナーゼをコードするショウジョウバエおよびヒトのポリヌクレオチドの単離、このポリヌクレオチドによってコードされるポリペプチド、ならびにこのポリヌクレオチドおよびポリペプチドを利用する方法 | |
| US20100056611A1 (en) | MN/CA9 Splice Variants | |
| US7910691B2 (en) | MN gene and protein | |
| US7713704B1 (en) | MN gene and protein | |
| US20080199881A1 (en) | MN Gene and Protein | |
| US20080026992A1 (en) | Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family | |
| US20080214787A1 (en) | MN Gene and Protein | |
| US7098311B2 (en) | Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors | |
| JP2005515751A (ja) | Ｎｋｄタンパク質のヒトホモログおよび非ヒト霊長類ホモログ、ならびにそれをコードする核酸配列、ならびにこれらの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050405 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050705 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051005 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061127 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070125 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100202 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110202 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120202 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130202 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140202 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |